相关实验视频

Updated: Apr 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

乳腺癌的病理完整反应

Alberto Ocana1, Bostjan Seruga2, Eitan Amir3

  • 1Translational Oncology Research Unit, Albacete University Hospital, Albacete 02006, Spain.

Lancet (London, England)
|February 24, 2015
PubMed
概括

No abstract available in PubMed .

更多相关视频

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.4K

相关实验视频

Last Updated: Apr 17, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

15.3K
Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer
07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

7.4K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Tumor Progression02:07

Tumor Progression

8.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
8.0K

通过共同作者、期刊和引用图与本文相关的文章。

Tumor-type specific methylation patterns of MTAP in human samples and cell lines.

Clinical epigenetics·2026

Genetic testing for cancer predisposition syndromes in pediatric cancer patients: current practices and recommendations - a systematic review.

Radiology and oncology·2026

From trial-and-error to inverse design: how AI is redefining drug delivery systems.

Drug discovery today·2026

Cooperative molecular interaction networks govern PARP1 inhibitor selectivity and binding affinity.

PLoS computational biology·2026

Guanidine-Based Ligands in Bioinorganic Chemistry: Coordination Modes and Applications in Anticancer Metallodrugs.

Bioinorganic chemistry and applications·2026

Comparative Assessment of Free Energy Computational Methods for Revealing the Interactions Driving PARP1 Selective Inhibition.

Journal of chemical information and modeling·2026

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Expanding the Horizon of CAR-T Cell Therapy: Present Obstacles and New Strategies for Future CARs in Solid Tumors.

Anti-cancer agents in medicinal chemistry·2026

Radical Hysterectomy for Non-Endometrioid Endometrial Cancer With Cervical Involvement: A Retrospective Cohort Study.

Journal of surgical oncology·2026

Ischemic Postconditioning in Patients With Acute Stroke With Successful Recanalization After Endovascular Therapy: A Pilot Randomized Controlled Trial.

Stroke·2026

Depth-sensitive optical property characterization using multi-frequency laparoscopic spatial frequency domain imaging.

Biomedical optics express·2026

Metabolomic and inflammatory signatures in congenital hypothyroidism: a longitudinal analysis of levothyroxine response.

Frontiers in endocrinology·2026

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) Monitoring of Rapidly Progressive Low-Risk Cutaneous Melanoma: A Case Report of Durable Response to Combined Stereotactic Body Radiotherapy (SBRT) and Immunotherapy.

Cureus·2026
查看所有相关文章
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策
Jove
Visualize
联系我们